BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an…Read More

You might also be interested in reading Grayscale Crosses $45 Billion in Cryptocurrency Assets under Management.